Wrap Text
Dealings in securities by directors, a prescribed officer, directors of a major subsidiary and the company secretary
LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
ISIN: ZAE000145892
JSE and A2X share code: LHC
("Life Healthcare" or "the Company")
LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa with limited liability)
(Registration number: 2016/273566/06)
LEI: 3789SJPQJZF8ZYXTZ394
Bond company code: LHFI
DEALINGS IN SECURITIES BY DIRECTORS, A PRESCRIBED OFFICER, DIRECTORS OF A
MAJOR SUBSIDIARY AND THE COMPANY SECRETARY
In terms of the Listings Requirements of JSE Limited, Life Healthcare shareholders and noteholders
are hereby advised of the following dealings in securities under the rules of the Company's Matching
Share Arrangement ("MSA") and Long-Term Incentive Plan.
The third tranche of the MSA vested at the end of December 2025. The performance conditions, in
respect of these shares have been met. The Human Resources and Remuneration Committee, via a
majority, has approved the vesting. The closing price on date of Human Resources and Remuneration
Committee approval, i.e. 12 January 2026 was used as the vesting price, which is R11.60 per share.
The following shares will be delivered to the trading accounts on an off-market basis to each of the
Directors and Prescribed Officer of the Company, which will be held directly beneficial as follows:
Details of recipient Number of Life Total value LHC shares
Healthcare attributable to sold to
shares delivered award applying the settle tax
cumulative average liability
price of the share
purchase of R11.60
Peter Gerard Wharton-Hood 287,570 R3,335,812 -
Director
Petrus Phillippus van der Westhuizen 116,868 R1,355,669 52,590
Director
Adam Mills Pyle 65,075 R754,870 29,283
Prescribed Officer
Petrus Phillippus van der Westhuizen (Chief Financial Officer) has sold a portion of shares that have
vested through the Company's MSA to settle the tax liability:
Name of the Director: Petrus Phillippus van der Westhuizen
Nature of transaction: On market disposal of shares
Class of securities: Ordinary shares
Nature of interest: Direct beneficial
Clearance obtained: Yes
Date of transaction: 12 January 2026
Number of securities: 52,590
Disposal price per share: R11.4120
The total value of the transaction: R600,157.08
Adam Mills Pyle (Chief Growth and Strategy Officer) has sold a portion of shares that have vested
through the Company's MSA to settle the tax liability:
Name of the Prescribed Officer: Adam Mills Pyle
Nature of transaction: On market disposal of shares
Class of securities: Ordinary shares
Nature of interest: Direct beneficial
Clearance obtained: Yes
Date of transaction: 12 January 2026
Number of securities: 29,283
Disposal price per share: R11.4120
The total value of the transaction: R334,177.60
Craig Ian Koekemoer (Chief Operating Officer) has sold his shares that have vested through the
Company's Long-Term Incentive Plan, as communicated to the market on 9 January 2026.
Name of Director of a major subsidiary: Craig Ian Koekemoer
Name of Company: Life Healthcare
Nature of transaction: On market disposal of shares
Date of transaction: 13 January 2026
Number of securities: 370,000
Class of securities: Ordinary shares
The total value of the transaction: R4,203,582.10
Volume weighted average price per share: R11.3610
Highest price per share: R11.3800
Lowest price per share: R11.3600
Nature of interest: Direct beneficial
Clearance obtained: Yes
Joshila Ranchhod (Company Secretary) has sold a portion of her shares that have vested through the
Company's Long-Term Incentive Plan, as communicated to the market on 9 January 2026.
Name of Company Secretary: Joshila Ranchhod
Name of Company: Life Healthcare
Nature of transaction: On market disposal of shares
Date of transaction: 14 January 2026
Number of securities: 175,450
Class of securities: Ordinary shares
The total value of the transaction: R2,007,611.29
Volume weighted average price per share: R11.4426
Highest price per share: R11.5000
Lowest price per share: R11.4200
Nature of interest: Direct beneficial
Clearance obtained: Yes
Kurt Aston Wylie (New Business Executive) has sold his shares that have vested through the
Company's Long-Term Incentive Plan, as communicated to the market on 9 January 2026.
Name of Director of a major subsidiary: Kurt Aston Wylie
Name of Company: Life Healthcare
Nature of transaction: On market disposal of shares
Date of transaction: 15 January 2026
Number of securities: 328,526
Class of securities: Ordinary shares
The total value of the transaction: R3,750,285.24
Volume weighted average price per share: R11.4155
Highest price per share: R11.5000
Lowest price per share: R11.3500
Nature of interest: Direct beneficial
Clearance obtained: Yes
Clearance to deal has been obtained for all the transactions above in terms of the Listings Requirements
of the JSE.
Dunkeld
16 January 2026
Equity Sponsor
RAND MERCHANT BANK (A division of FirstRand Bank Limited)
Debt Sponsor
Questco Corporate Advisory
Date: 16-01-2026 02:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
